Vaxcyte

Vaxcyte is a clinical-stage vaccine company that engineers high-fidelity vaccines against bacterial diseases. Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) - the broadest-spectrum PCV in clinical development - and is being studied for the prevention of invasive pneumococcal disease in a Phase 3 adult programme and a Phase 2 infant programme. The pipeline also includes VAX-A1 for Group A Strep and VAX-GI for Shigella.

Central to the company's approach is XpressCF®, a proprietary cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. The platform is used to re-engineer how complex vaccines are made, addressing limitations of conventional cell-based manufacturing and producing vaccines with enhanced immunological benefits. Related technical work spans vaccine engineering, conjugate vaccine development, protein engineering and immunology.

The company has raised over $690 million in total capital and is listed on NASDAQ. It operates across the biotechnology, vaccines, pharmaceuticals and infectious disease prevention sectors, with an stated mission of protecting humankind from the consequences of bacterial diseases.